Physician profile
Abdul Chughtai
NPI 1619959855
$1,722.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2020: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $293.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $228.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $154.34 | 2019 | |
| Lundbeck LLC | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2019 | |
| Novo Nordisk INC | $116.29 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $108.40 | 2019 | |
| Astellas Pharma US INC | $87.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.50 | 2020 | |
| Amgen INC. | $53.70 | 2019 | |
| Tactile Systems Technology INC | $50.32 | 2020 | |
| Chiesi USA, INC. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Chughtai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.